Please provide your email address to receive an email when new articles are posted on . Accounting for the presence of multiple, concurrent central lines when calculating central line-associated ...
Acalabrutinib was associated with increased PFS and a 24% reduction in time to next treatment or death in long-term results. Concurrent acalabrutinib, bendamustine, and rituximab (ABR) in the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback